An optimal siRNA candidate should inhibit between 30 and 50% of PMP22 expression and restore normal levels of Pmp22 protein, which are increased by 1.5- to 2-folds in CMT1A patients as mention by Svaren et al.26. The gene discussed is PMP22; the disease is Charcot-Marie-Tooth disease type 1A.